Healthcare Industry News: IDev Technologies
News Release - August 28, 2006
IDEV(R) Technologies, Inc. Gains a 510(k) Clearance for Its Interwoven Nitinol Self-Expanding Stent: SUPERA(TM)HOUSTON--(HSMN NewsFeed)--Aug. 28, 2006--IDev Technologies, Inc., an emerging leader in the development and marketing of minimally invasive stent technologies, announced today that the company received a 510(k) clearance from FDA for the first interwoven nitinol self-expanding stent available in the United States for palliative treatment of malignant strictures in the biliary tree. The newly approved SureSave(TM) Stent will be renamed SUPERA(TM).
Thomas M.Tully, Chairman and CEO commented, "U.S. 510(k) approval for the IDEV stent is the second critical step toward the global commercialization of this novel technology. The first step came earlier this year when IDev Technologies Inc. received a CE Mark for both Vascular and Non-Vascular applications for this device. The remaining critical step for the organization lies in packaging this technology in a simple, easy to use, system for widespread utilization among physicians. In addition, IDEV will continue to mobilize toward a global launch of its stent in select high volume medical centers in the U.S. and Europe in early 2007."
About IDev Technologies, Inc.
IDev Technologies, Inc. ("IDEV") is an innovator and developer of next generation medical devices for use in the interventional radiology, vascular surgery and cardiology device marketplace. IDEV is based in Houston, Texas and its current portfolio contains over thirty technologies exclusively licensed from the M.D. Anderson Cancer Center, representing over a $5.0 billion dollar market opportunity worldwide.
Source: IDEV Technologies
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.